Hercules Capital, Inc. (NYSE: HTGC) announced on June 30, 2025, that it has entered into a $275 million non-dilutive senior secured term loan facility with Dyne Therapeutics, Inc. This financing aims to provide strategic flexibility through key inflection points for Dyne Therapeutics.
Under the terms of the agreement, $100 million was funded upfront, with an additional $175 million tied to the achievement of specific milestones. This capital infusion supports Dyne Therapeutics, a clinical-stage company focused on genetically driven neuromuscular diseases.
This partnership underscores Hercules Capital's continued commitment to the life sciences sector, supporting innovative companies in their clinical development. The non-dilutive nature of the financing is beneficial for Dyne Therapeutics' existing shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.